STAGE IV UTERINE CORPUS CANCER AJCC V8
Clinical trials for STAGE IV UTERINE CORPUS CANCER AJCC V8 explained in plain language.
Never miss a new study
Get alerted when new STAGE IV UTERINE CORPUS CANCER AJCC V8 trials appear
Sign up with your email to follow new studies for STAGE IV UTERINE CORPUS CANCER AJCC V8, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New cancer drug IACS-6274 enters early human testing
Disease control Recruiting nowThis early-phase trial is testing a new drug called IACS-6274, either alone or combined with other cancer drugs, in 54 adults with advanced solid tumors (such as melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. Th…
Matched conditions: STAGE IV UTERINE CORPUS CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Experimental drug plus radiation shows promise for recurrent gynecologic cancers
Disease control Recruiting nowThis early-phase trial is testing the drug talazoparib together with radiation therapy in 24 women whose gynecologic cancer (ovarian, endometrial, cervical, or related cancers) has come back after previous treatment. Talazoparib blocks enzymes that cancer cells need to grow, and …
Matched conditions: STAGE IV UTERINE CORPUS CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Electric field device combined with drugs tested for advanced cancers
Disease control Recruiting nowThis early-phase trial tests a wearable device that creates electric fields (tumor treating fields) combined with either cabozantinib or nab-paclitaxel and atezolizumab in 43 people with advanced solid tumors in the abdomen or chest. The goal is to find the safest dose and see if…
Matched conditions: STAGE IV UTERINE CORPUS CANCER AJCC V8
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Chemotherapy as a fine mist: could PIPAC reduce side effects for abdominal cancer patients?
Disease control Recruiting nowThis early-phase trial tests a technique called PIPAC, which turns liquid chemotherapy into a fine mist sprayed directly into the abdomen during a minimally invasive surgery. It aims to see if this approach is safe and causes fewer side effects than standard chemotherapy. The stu…
Matched conditions: STAGE IV UTERINE CORPUS CANCER AJCC V8
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New platform aims to predict which cancer treatments will work
Knowledge-focused Recruiting nowThis study collects tissue samples from people with various advanced or early-stage cancers to train a diagnostic platform called Elephas. The goal is to see how accurately it can predict whether a patient will respond to immunotherapy or chemoimmunotherapy. About 324 participant…
Matched conditions: STAGE IV UTERINE CORPUS CANCER AJCC V8
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC